Allinky secures patent grant in China

Allinky is thrilled to announce that on December 31st, 2024, the China National Intellectual Property Administration (CNIPA) granted a patent for its invention, ‘PYRIDIN-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO INTERLEUKIN 1 BETA.’ This milestone follows the successful patent grants by the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO), solidifying Allinky’s global intellectual property strategy and expanding its reach into one of the most dynamic healthcare markets in the world.

The grant of this patent in China highlights the international significance of Allinky’s breakthrough invention and its potential to transform the treatment landscape for inflammatory and fibrotic conditions. With this recognition, Allinky continues to position itself as a leader in biotech innovation, driving progress through robust research and development while ensuring protection for its cutting-edge technologies across key global markets.